What's happened
Uganda is expanding local pharmaceutical production and procurement, arguing for greater government purchasing of domestically manufactured medicines. Authorities say this shift aims to reduce external dependency, create jobs and strengthen health resilience while navigating funding and demand challenges.
What's behind the headline?
What’s driving the shift
- Government policy aims to reduce dependence on imports for medicines and vaccines.
- Local manufacturers are expanding portfolios to cover HIV, malaria, TB, sickle-cell disease, diabetes and more.
- Demand predictability from government purchases is cited as key to sustaining local production.
What’s at stake
- More local jobs and value-added spending on inputs like packaging and raw materials.
- Risks include mismatches between capacity and guaranteed demand, and the need for quality controls.
Forecast
- If governments provide predictable demand and remove procurement bottlenecks, local production could become a stable backbone for Africa’s medicines supply.
How we got here
Uganda has been pushing to localize pharmaceutical procurement and scale up domestic production for years. Government directives since 2016 have steered public procurement toward locally manufactured medicines, expanding the budget for the National Medical Stores and boosting investment in new facilities and products.
Our analysis
All Africa reports that Uganda’s government procurement now prioritizes locally manufactured medicines, with the NMS’s share of locally sourced medicines rising to about 64-60% from 2015-2026. UPMA notes investments exceeding $500 million and thousands of jobs. The Uganda State House team emphasizes expanding product eligibility and avoiding monopolies in off-take agreements.
Go deeper
- Will Uganda’s approach be scalable to neighboring countries?
- What other barriers (financial, regulatory, supply chain) must be addressed to sustain growth?
- How might off-take agreements affect competition among local firms?